Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with histologically- or cytologically-documented NSCLC
Locally advanced, unresectable (Stage III) NSCLC
World Health Organisation (WHO) performance status 0-1
At least one measurable lesion, not previously irradiated
Must have a life expectancy of at least 12 weeks at randomization
You may not be if
Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs.
Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.
History of allogeneic organ transplantation
Active or prior documented autoimmune or inflammatory disorders
Uncontrolled intercurrent illness
History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
Mixed small cell and NSCLC histology
Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling
Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.
Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.
